留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

抗肿瘤坏死因子α单克隆抗体治疗克罗恩病的关键问题:再读共识

曹倩

曹倩. 抗肿瘤坏死因子α单克隆抗体治疗克罗恩病的关键问题:再读共识[J]. 协和医学杂志, 2017, 8(4-5): 207-209. doi: 10.3969/j.issn.1674-9081.2017.05.003
引用本文: 曹倩. 抗肿瘤坏死因子α单克隆抗体治疗克罗恩病的关键问题:再读共识[J]. 协和医学杂志, 2017, 8(4-5): 207-209. doi: 10.3969/j.issn.1674-9081.2017.05.003
Qian CAO. The Crucial Problems in the Treatment of Crohn's Disease with Anti-tumor Necrosis Factor-α Monoclonal Antibody[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 207-209. doi: 10.3969/j.issn.1674-9081.2017.05.003
Citation: Qian CAO. The Crucial Problems in the Treatment of Crohn's Disease with Anti-tumor Necrosis Factor-α Monoclonal Antibody[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 207-209. doi: 10.3969/j.issn.1674-9081.2017.05.003

抗肿瘤坏死因子α单克隆抗体治疗克罗恩病的关键问题:再读共识

doi: 10.3969/j.issn.1674-9081.2017.05.003
详细信息
    作者简介:

    曹倩  电话:0571-86006642,E-mail:caoq@srrsh.com

  • 中图分类号: R574.1

The Crucial Problems in the Treatment of Crohn's Disease with Anti-tumor Necrosis Factor-α Monoclonal Antibody

More Information
  • 摘要: 炎症性肠病是一组病因尚不十分明确的慢性非特异性肠道炎症性疾病, 包括溃疡性结肠炎和克罗恩病, 以抗肿瘤坏死因子α单克隆抗体为代表的生物制剂在炎症性肠病中主要用于治疗克罗恩病。《抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)》在本期发布, 通过再读新版共识, 重点探讨抗肿瘤坏死因子α单克隆抗体治疗克罗恩病的部分关键问题, 以帮助临床医生提高认识。
  • [1] Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease:the ACCENT I randomised trial[J].Lancet, 2002,359:1541-1549. doi:  10.1016/S0140-6736(02)08512-4
    [2] Sands BE,Anderson FH, Bernstein CN,et al. Infliximab maintenance therapy for fistulizing Crohn's disease[J].N Engl J Med,2004,350:876-885. doi:  10.1056/NEJMoa030815
    [3] Bouguen G, Siproudhis L, Gizard E,et al. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab[J].Clin Gastroenterol Hepatol,2013,11:975-981. doi:  10.1016/j.cgh.2012.12.042
    [4] Singh S, AI-Darmaki A,Frolkis AD,et al.Postoperative mortality among patients with inflammatory bowel diseases:a systematic review and meta-analysis of population-based studies[J].Gastroenterology,2015,149:928-937. doi:  10.1053/j.gastro.2015.06.001
    [5] Amiot A, Setakhr V, Seksik P, et al. Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy:a cohort study from the GETAID[J]. Am J Gastroenterol,2014,109:1443-1449. doi:  10.1038/ajg.2014.183
    [6] Colombel JF, Sandborn WJ, Reinisch W,et al. Infliximab, azathioprine,or combination therapy for Crohn's disease[J]. N Engl J Med,2010,362:1383-1395. doi:  10.1056/NEJMoa0904492
    [7] Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial[J].Gut,2014,63:88-95. doi:  10.1136/gutjnl-2013-304984
    [8] Waugh AW,Garg S,Matic K,et al.Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab:long-term follow-up of a single centre cohort[J].Aliment pharmacol Ther,2010,32:1129-1134. doi:  10.1111/j.1365-2036.2010.04446.x
    [9] D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization:when to start, when to stop, which drug to choose, and how to predict response?[J]. Am J Gastroenterol,2011,106:199-212. doi:  10.1038/ajg.2010.392
  • 加载中
计量
  • 文章访问数:  19
  • HTML全文浏览量:  3
  • PDF下载量:  7
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-07-04
  • 刊出日期:  2017-09-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!